Quantib, a leader in medical AI software, strives for faster and more accurate diagnoses, supporting adequate and timely patient care. Its products can detect changes in tissue sooner than would be possible with the naked eye. Quantib has multiple products cleared by FDA and CE marked, which are focused on the detection of changes in the brain related to diseases such as dementia and MS. It has a strong pipeline of new products focused on oncology and osteoarthritis.

“Over the past years we have worked very closely with Holland Capital and it’s advisors, we are in touch on a weekly basis. They are really supporting us beyond what you would normally expect from an investor and are a very welcome part of our team.”

Arthur Post-Uiterweer

Managing Director, Quantib

Virtual Affairs




Medical Artificial Intelligence (AI)/Machine learning.


Investment period:

November 2017


Transaction type:

Growth Capital